InvestorSoup.com issues Trading Outlook for Jazz Pharmaceuticals Inc.
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, September 17, 2009 ) DALLAS, Texas - InvestorSoup.com announces an investment report featuring JAZZ Pharmaceuticals Inc. (JAZZ).
The investment report on JAZZ Pharmaceuticals Inc. (JAZZ) should be of particular interest other pharmaceutical and biotechnology companies Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), GlaxoSmithKline (NYSE: GSK) and Cephalon (NASDAQ: CEPH).
It is available at: http://www.investorsoup.com/lp/JAZZ
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Jazz Pharmaceuticals Inc. (JAZZ) is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder; and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.
In the report, the analyst notes:
“JAZZ reported total revenues for the second quarter at $37.3 million, compared to $15.5 million for the quarter ended June 30, 2008. The Company noted that revenues for the second quarter included a $10.0 million milestone payment from UCB Pharma Limited that was received in July 2008 and recognized as revenue when the last patient completed the second JZP-6 phase III clinical study in April 2009.
“Sales of LUVOX CR, JAZZ’s once-a-day drug to treat social anxiety disorder, rose to $4.1 million from $714,000 in the year-ago quarter; the Company expects net sales for LUVOX CR between $15 million and $18 million. For the full year, the company expects total revenue between $112 million and $122 million.”
To read the entire report visit: http://www.investorsoup.com/lp/JAZZ
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.
The investment report on JAZZ Pharmaceuticals Inc. (JAZZ) should be of particular interest other pharmaceutical and biotechnology companies Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), GlaxoSmithKline (NYSE: GSK) and Cephalon (NASDAQ: CEPH).
It is available at: http://www.investorsoup.com/lp/JAZZ
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Jazz Pharmaceuticals Inc. (JAZZ) is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder; and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.
In the report, the analyst notes:
“JAZZ reported total revenues for the second quarter at $37.3 million, compared to $15.5 million for the quarter ended June 30, 2008. The Company noted that revenues for the second quarter included a $10.0 million milestone payment from UCB Pharma Limited that was received in July 2008 and recognized as revenue when the last patient completed the second JZP-6 phase III clinical study in April 2009.
“Sales of LUVOX CR, JAZZ’s once-a-day drug to treat social anxiety disorder, rose to $4.1 million from $714,000 in the year-ago quarter; the Company expects net sales for LUVOX CR between $15 million and $18 million. For the full year, the company expects total revenue between $112 million and $122 million.”
To read the entire report visit: http://www.investorsoup.com/lp/JAZZ
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.
Contact Information:
Investor Soup
Jeffrey Brown
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Investor Soup
Jeffrey Brown
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |